Present immunotherapy approaches for the destruction of tumor cells include cancer vaccines, immune checkpoint blockades such as PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, induction of cytotoxic T-lymphocytes, adoptive cell transfer-based therapy, and modulation of the TME to increase CTL activity [67,68]. This evidence concerns the gene PDCD1 and neoplasm.